The adrenal steroid status in relation to inflammatory cytokines (interleukin‐6 and tumour necrosis factor) in polymyalgia rheumatica
Authors:
- R. H. StraubRSR. H. Straub
- T. GlückTGT. Glück
- M. CutoloMCM. Cutolo
- J. GeorgiJGJ. Georgi
- K. HelmkeKHK. Helmke
- J. SchölmerichJSJ. Schölmerich
- P. VaithPVP. Vaith
- B. LangBLB. Lang
Open Access
- 1 June 2000
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 39 (6) , 624-631
Abstract
Objectives. To determine the correlation between inflammatory cytokines and adrenal hormones in patients with polymyalgia rheumatica (PMR) and to compare the ratio of serum cortisol and androstenedione (ASD) or dehydroepiandrosterone sulphate (DHEAS) in normal subjects with PMR patients. Methods. In 102 patients with PMR (32 beginning and 70 chronic disease) and 31 age‐matched and sex‐matched healthy subjects, ASD, cortisol, DHEAS, interleukin‐6 (IL‐6), and tumour necrosis factor (TNF) were measured by immunometric assays. Results. Serum levels of IL‐6 were elevated in patients with PMR as compared with normal subjects (10.0 ± 1.6 vs 2.1 ± 0.1 pg/ml, P = 0.01), which was not found for TNF. In PMR patients, serum levels of IL‐6 were positively correlated with serum levels of ASD (P < 0.001), cortisol (P < 0.001), and DHEAS (P = 0.038) irrespective of corticosteroid treatment. Serum levels of cortisol in relation to IL‐6 were significantly lower in patients with chronic disease and long‐standing corticosteroid administration as compared with patients with recent onset of the disease and without corticosteroid therapy (P < 0.01). Conclusions. In PMR, as expected, there was an increase in IL‐6 serum levels that was associated with elevated serum levels of ASD, DHEAS, and cortisol which was more marked in patients with recent‐onset disease and without corticosteroids. However, serum levels of cortisol in patients with and without corticosteroids were lower than expected by considering the inflammatory status (increased IL‐6). This may indicate a change in the hypothalamic–pituitary–adrenal (HPA) axis responsiveness to inflammatory stimuli such as IL‐6 during chronic disease. Furthermore, there seems to be a shift of biosynthesis to cortisol in relation to DHEAS or ASD in chronic disease.Keywords
This publication has 37 references indexed in Scilit:
- Peroxisome Proliferator-activated Receptor α Activation Modulates Cellular Redox Status, Represses Nuclear Factor-κB Signaling, and Reduces Inflammatory Cytokine Production in AgingJournal of Biological Chemistry, 1998
- Leukocytes modulate 11β-hydroxysteroid dehydrogenase (11β-HSD) activity in human granulosa-lutein cell culturesMolecular and Cellular Endocrinology, 1997
- Serum Dehydroepiandrosterone (DHEA) and DHEA-Sulfate (DHEA-S) in Alzheimer's Disease and in Cerebrovascular Dementia.Endocrine Journal, 1996
- DHEAS Inhibits TNF Production in Monocytes, Astrocytes and Microglial CellsNeuroimmunomodulation, 1996
- The Hypothalamic–Pituitary–Adrenal Axis and Immune-Mediated InflammationNew England Journal of Medicine, 1995
- Impairment of Adrenocortical Function Associated with Increased Plasma Tumor Necrosis Factor-Alpha and Interleukin-6 Concentrations in African TrypanosomiasisNeuroimmunomodulation, 1994
- Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humansThe Journal of Clinical Endocrinology & Metabolism, 1993
- Suppression of hypothalamic-pituitary-adrenal axis responsiveness to stress in a rat model of acute cholestasis.Journal of Clinical Investigation, 1993
- Trends in incidence and clinical presentation of temporal arteritis in olmsted county, minnesota, 1950–1985Arthritis & Rheumatism, 1988
- An evaluation of criteria for polymyalgia rheumatica.Annals of the Rheumatic Diseases, 1979